Trials / Completed
CompletedNCT04805736
Microwave Ablation Combined With Camrelizumab in the Treatment of Early Breast Cancer
A Pilot Study of Single-Dose Camrelizumab and/or Microwave Ablation in Women With Early-Stage Breast Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University · Academic / Other
- Sex
- Female
- Age
- 20 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Ablative therapy, as a local treatment modality for tumors, has an immune activating effect. To explore the synergistic effect of microwave ablation combined with PD-1 inhibitors, this prospective, open-label, multi-cohort, single-center clinical study was conducted. To compare the feasibility and safety of preoperative microwave ablation alone, with or without camrelizumab in patients with early newly diagnosed breast cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Microwave Ablation | Image-guided microwave ablation 7-10 days prior to surgery |
| DRUG | Camrelizumab | Camrelizumab 200 mg was given a few days after microwave ablation |
| PROCEDURE | Breast Surgery | Standard of care breast conserving surgery or radical mastectmoy |
Timeline
- Start date
- 2021-03-25
- Primary completion
- 2023-04-30
- Completion
- 2023-04-30
- First posted
- 2021-03-18
- Last updated
- 2024-01-05
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04805736. Inclusion in this directory is not an endorsement.